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Conditional Deletion of Smad1 
Ameliorates Glomerular Injury in 
Progressive Glomerulonephritis
Makoto Araki1,2, Takeshi Matsubara1, Hideharu Abe2, Kazuo Torikoshi1, Akira Mima2, 
Noriyuki Iehara1, Atsushi Fukatsu1, Toru Kita3, Hidenori Arai4 & Toshio Doi2
Matrix expansion and cell proliferation are concomitantly observed in various glomerular injuries. 
However, the molecular mechanisms responsible for these changes have not been fully elucidated. 
We have reported that Smad1 is a key signalling molecule that regulates the transcription of type IV 
collagen (Col4) in mesangial matrix expansion and is thereby involved in glomerular injury in an acute 
model of glomerulonephritis. In this study, we addressed the role of Smad1 signalling in accelerated 
nephrotoxic nephritis (NTN), a model of progressive glomerulonephritis, using conditional deletion 
of Smad1 in Rosa26CreERT2 mice (Smad1-CKO). Mesangial matrix expansion in the Smad1-CKO mice 
with NTN was significantly inhibited compared with that in wild type mice with NTN, which was 
consistent with the decrease in Col4 expression level. On the other hand, STAT3 activation and cell 
proliferation were not influenced by Smad1 deletion in the NTN model. Therefore, we investigated 
another factor that activates cell proliferation in the absence of Smad1. Id2 induced VEGF secretion and 
subsequent STAT3 activation, independently of Smad1 expression in mouse mesangial cells. Here we 
show that Smad1 plays an important role in the development of glomerular injury without affecting cell 
proliferation, in progressive glomerulonephritis.
The global burden of end-stage renal disease is a significant public health threat. Therefore, it is urgent 
that researchers elucidate the mechanisms of kidney disease and develop adaptive treatment strategies. 
Glomerulonephritis (GN) is a common cause of end-stage renal disease and glomerulosclerosis is defined as the 
segmental or global collapse or closure of capillary loops with associated extracellular matrix (ECM) overpro-
duction in the mesangial area. Excessive proliferation of cells and subsequent overproduction of ECM contribute 
significantly to the pathogenesis of GN and glomerulosclerosis. Mesangial matrix expansion is characterized by 
increased deposition of ECM, such as type IV collagen (Col4), laminin, type I and III collagens, heparan sulphate 
proteoglycan, and fibronectin1–3. Among these factors, Col4 is the most important component of the mesangial 
matrix and is distributed in all layers of the basement membrane, forming its structural frame.
We have previously reported that Smad1 transcriptionally regulates the expression of Col4 under dia-
betic conditions in vitro and in vivo4. Moreover, we have shown that administration of anti-PDGFβ-receptor 
(anti-PDGFβR) antibody (APB5) to the mesangial-proliferative model of GN in Thy1 GN rats attenuates glomer-
ular cell proliferation and glomerulosclerosis and Smad1 activation. However, the Thy1 GN model is self-limiting 
and spontaneously reversible. In contrast, most serious glomerular diseases develop more progressively and result 
in kidney failure. Therefore, it is necessary to investigate whether blockade of PDGFβR can exert a similar effect in 
progressive forms of GN. In this study, we analysed a well-established model of severely progressive GN, induced 
nephrotoxic nephritis (NTN), using conditional Smad1 knockout (Smad1-CKO) mice.
It is well known that platelet-derived growth factor BB (PDGF-BB) plays a central role in GN5–7, and pharma-
cological administration of PDGF-BB causes mesangial cell (MC) proliferation and ECM accumulation7. We have 
also shown that PDGF-BB phosphorylates Smad1 and induces the expression of Col4 via signal transducer and 
activator of transcription 3 (STAT3) in cultured MCs8. However, the functional role of Smad1 and its relation-
ship with the PDGF-BB–STAT3 signalling pathway in the development of GN in vivo remains to be elucidated. 
Moreover, it remains unclear which molecules determine the progression or remission of GN.
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To address these issues, we created and validated Smad1-CKO mice and used them to examine the role 
of Smad1 in murine NTN. In addition, we investigated the relationship between Smad1 activation and the 
PDGF-BB signalling pathway. We confirmed that Smad1 is essential for progressive glomerular injury in this 
model. Furthermore, we found that novel molecular mechanisms underlie the Smad1-independent signalling 
pathway and activate cell proliferation and STAT3.
Results
Morphological glomerular changes and activation of PDGF signalling pathway in glomeruli 
in NTN. NTN is used as a model of acute and progressive renal injury9,10. Soon after Nephrotoxic serum 
(NTS) injection, mice rapidly develop severe glomerulonephritis with hypertrophy, and glomeruli are replaced 
by fibrotic tissue. We have previously reported that Thy1 rat model exhibit remission of both proliferative changes 
and ECM expansion simultaneously8. Therefore, our aim in this study was to gain some clues for molecular mech-
anisms underlying the difference between reversible and irreversible proliferative changes in glomerulonephritis. 
For this study, we sacrificed the mice 21 days after the injection, corresponding to the change from glomerular 
hypertrophy to glomerulosclerosis11 (Fig. 1a–d,q). Microscopic analysis of NTN showed diffuse proliferation 
of the mesangial matrix and an expansion of the mesangial area (Fig. 1c). In addition, immunohistochemical 
examination demonstrated the overexpression of Col4 in the expanded mesangial area of glomeruli (Fig. 1g). 
NTN also exhibited significantly enhanced expression of PDGF-BB and PDGFβR in the glomeruli (Fig. 1k,o). 
The APB5 monoclonal antibody specifically binds to PDGFβR and blocks PDGF signalling as described 
previously12,13. We treated NTN mice with APB5 to block PDGFβR-mediated signalling because PDGF-BB is 
involved in ECM expansion and proliferative changes. As expected, NTN mouse glomeruli exhibited glomerulo-
sclerosis with marked ECM expansion and cell proliferation. APB5 treatment significantly inhibited the glomer-
ular hypertrophy (Fig. 1c,d,q). As shown in Fig. 1a, this glomerular hypertrophy was not affected by the control 
antibody treatment. We isolated glomeruli using laser-captured microdissection (LCM) techniques, extracted 
mRNA, and analysed gene expression in the glomeruli. Expression of Col4 in the glomeruli showed consist-
ent results with quantitative RT-PCR (qPCR) analysis (Fig. 1r). Treatment with APB5 significantly suppressed 
the overexpression of both PDGF-BB and PDGFβR (Fig. 1l,p,s). Correlation between the expressions of phos-
pho-Smad1 (pSmad1) and Col4 was expected based on our previous study. Unlike these inhibitory effect of 
APB5, the significant amelioration of renal function was observed in albumin excretion at day 7 alone, implying 
that compensatory response may be induced in this model (Fig. 1t). We conducted experiments using the Smad1-
CKO mice to prove the direct relationship between Smad1 and Col4 in vivo.
Expression of Smad1 and pSmad1 in glomeruli in NTN. We examined Smad1 signal activation in 
NTN mice by immunohistochemical analysis. Smad1 and pSmad1 were barely detectable in control glomeruli 
and glomeruli treated with APB5 alone (Fig. 2a,b,e,f). Although Smad1 was extensively induced and activated 
in the glomeruli at day 21 in NTN mice (Fig. 2c,g), the activation of Smad1 signallings was inhibited by APB5 
treatment (Fig. 2d,h). We then performed a qPCR using mRNA from isolated glomeruli and found that both the 
expression of Smad1 and the number of pSmad1–positive cells were suppressed by APB5 treatment in proportion 
to the reduction in Col4 (Fig. 2i,j). The mRNA expression levels of Smad1 was significant correlated with those of 
Col4 in NTN treatment both with and without APB5 administration (Fig. 2k,l).
Generation of Smad1 conditional knockout mice. We initially crossed Rosa26CreERT2 mice with 
Smad1flox/− mice, as conventional deletion of the Smad1 gene results in early embryonic lethality prior to E10.5 
and before kidney organogenesis. First, we confirmed Cre expression in the kidneys of Rosa26-CreERT2 trans-
genic mice using lacZ detection. Adult R26R/R26-CreERT2 mice were given tamoxifen for 5 consecutive days, and 
recombination of the lacZ reporter was analysed 7 days after the last tamoxifen administration. In contrast to wild 
type (WT) mice, tamoxifen-administered Rosa26CreERT2 mice showed lacZ expression in the glomeruli. Double 
immunostaining for desmin and β-galactosidase indicated that tamoxifen also induced transgene expression 
in MCs (Fig. 3a). Next, we exploited a tamoxifen-inducible knockout system by crossing Rosa26CreERT2/+ mice 
with Smad1flox/− mice to generate Rosa26CreERT2/+, Smad1flox/− (Smad1-CKO) mice. We assessed Smad1 expression 
in the glomeruli of Smad1-CKO mice. QPCR and western blot analysis showed significantly decreased Smad1 
expression in the glomeruli of Smad1-CKO mice (Fig. 3b,c). The conventional (i.e. non-conditional) Smad1 
knockout mice exhibit embryonic lethality; however, Smad1flox/− or Smad1-CKO mice did not show any observ-
able differences from WT mice. In addition, there were no differences in body weight or blood pressure between 
Smad1-CKO mice and WT mice (Fig. 3d,e). Moreover, there were no significant morphological changes detected 
in the kidneys (Fig. 3f). Thus, conditional Smad1 gene ablation alone did not cause any phenotypic changes in 
the mice.
Smad1-CKO mice with NTN exhibited reduced glomerular injury and reduced Smad1 activation. 
We investigated the role of Smad1 in an experimental nephropathy model using Smad1-CKO mice. Twenty-one 
days after NTN-induction, we observed more extensive glomerulosclerosis in the NTN-induced WT mice 
(Fig. 4c), than in WT mice (Fig. 4a). We also noticed intense staining of Col4 in the WT mice after NTS treat-
ment (Fig. 4g), which is consistent with pSmad1 staining (Fig. 4k,w). In Smad1-CKO mice, glomerulosclerosis 
and intense Col4 staining were markedly reduced after NTS treatment (Fig. 4d,h,u). Moreover, to determine 
whether distinct signalling cascades are involved in mesangial proliferation and sclerosis, we examined the 
molecules downstream of Smad1, αSMA and Col14, and found an increase in Col1 and αSMA expression in 
NTS-treated mice (Fig. 4o,s), compared with that in non-treated WT mice (Fig. 4m,q). This increase was atten-
uated in Smad1-CKO mice (Fig. 4p,t). We then isolated glomeruli using LCM techniques, extracted mRNA, and 
analysed gene expression in the glomeruli. QPCR showed that Col4 expression was reduced in the Smad1-CKO 
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Figure 1. Morphological changes and effects of PDGFβR inhibition in NTN. The microscopic lesions 
in NTN mice appeared as the diffuse proliferation of mesangial matrix and expansion of the mesangial 
area. Immunohistochemical staining with anti-Col4 antibodies revealed the overexpression of Col4 in the 
expanded mesangial area of glomeruli from kidneys of NTN mice. NTN mics also showed significantly 
enhanced expression of PDGF-BB and PDGFβR in the glomeruli. Representative microscopic appearance of 
the glomerulus is shown. (a–d) PAM. (e–h) Col 4. (i–l) PDGF-BB. (m–p) PDGFβR. Original magnification 
for all panels was ×400. (q) PAM staining-positive area of the glomeruli. We collected at least 20 glomeruli in 
each sample. The expression levels of Col4 (Col4a1 and Col4a2) (r) and PDGF signals (s) in the glomeruli 21 
d after the initial NTS injection were analysed by qPCR and normalized to the expression of Rn18s. The values 
are expressed as the means ± SD. *P < 0.05. (t) Time course of changes in urinary albumin excretion in the two 
groups – control IgG- (○) and APB5- (●) treated mice, and serum Cre and BUN levels at day 21. Statistical 
analysis for comparison was performed using unpaired two-tailed Student’s t-test. NS, not significant, *P < 0.05 
(n = 5 mice/group).
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mice compared with WT mice after NTS treatment (Fig. 4v). Similarly, increased glomerular αSMA and Col1 
mRNA expressions in the NTN mice were almost eliminated in the Smad1-CKO mice (Fig. 4x,y). Next, we 
examined urinary albumin excretion (UAE) every 7 days and found that UAE in Smad1-CKO mice resulted in 
an albuminuria-lowering effect compared with that in WT mice; a significant decrease was observed at day 7 
(Fig. 4z).
Smad1-CKO mice did not show significant improvement in PDGF signalling and cell proliferation 
in NTN. In addition, we examined whether the genetic ablation of Smad1 affects PDGF signalling in glo-
meruli. The immunohistochemical staining patterns of PDGF-BB and PDGFβR (Fig. 5a,b,e,f) were not different 
between the WT and Smad1-CKO mice, and existence of Smad1 did not affect the expression levels of these 
signalling molecules after NTN treatment (Fig. 5c,d,g,h). QPCR of PDGF-BB showed similar results (Fig. 5q). 
We also found no difference in phosphorylated STAT3 (pSTAT3) expression or glomerular pSTAT3-positive 
Figure 2. Effects of PDGFβR inhibition on the induction and activation of Smad1 signal in NTN. 
Immunohistochemical staining of Smad1 and pSmad1 in glomeruli in NTN. NTN also showed significantly 
enhanced expression of Smad1 and pSmad1 in the glomeruli. APB5 treatment led to a significant decrease in 
expressions of these proteins. (a–d) Smad1. (e–h) pSmad1. (i) The expression levels of Smad1 in the glomeruli 
21 d after the initial NTS injection were analysed by qPCR and normalized to the expression of Rn18s. The 
values are expressed as the mean ± SD. *P < 0.05. (j) The number of cells positive for pSmad1. Fifty glomeruli 
were analysed for each sample. The values are expressed as the mean ± SD. *P < 0.05. Regression analysis 
comparing the changes in pSmad1 levels with changes in Col4a1 (k) and Col4a2 (l) expression mRNA levels in 
NTN model mice treated with control IgG (○) and APB5 (●).
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cell number between the WT and Smad1-CKO mice with or without NTS treatment (Fig. 5i–l,r). Similarly, glo-
merular PCNA expression and PCNA-positive cell number were not significantly different between the WT and 
Smad1-CKO mice (Fig. 5m–p,s).
Id2-VEGF signalling pathway is involved in cell proliferation independently of Smad1 in 
NTN. Although conditional Smad1 deletion suppressed the glomerular ECM expansion, proliferative changes 
in glomeruli were not inhibited. From these results, existence of yet another molecular mechanism that activates 
proliferative changes in the absence of Smad1 protein in glomeruli was predicted. In some cells, STAT3 is phos-
phorylated and activated by vascular endothelial growth factor (VEGF)-A and influences cell proliferation14,15. 
Thus, we hypothesized that secretion of VEGF-A may occur under the activated PDGF-BB signalling pathway 
independently of Smad1 expression in NTN. To test this possibility, we first examined the relationship between 
Smad1 and pSTAT3 expression in MCs treated with PDGF-BB. Under the stimulation of PDGF-BB, STAT3 was 
phosphorylated independently of Smad1 expression and activation (Fig. 6a). Glomerular VEGF-A expression 
was remarkably increased in NTN (Fig. 6b–d). However, conditional knockout of Smad1 did not influence the 
expression level of VEGF-A (Fig. 6e,f). Furthermore, we focused on the role of inhibitor of differentiation 2 (Id2), 
because Id2 was reported to induce VEGF-A secretion16,17. As expected, glomerular expression level of Id2 and 
VEGF-A were altered in tandem (Fig. 6g–k). In this model, ABP5 treatment showed a slight negative trend (not 
significant) at the number of pSTAT3- and PNCA-positive cells. In addition, expression levels of Id2 and VEGF-A 
in glomeruli were not reduced (Fig. S1). These results suggest that Id2-VEGF-A-STAT3 signalling pathway might 
be influenced by other receptors for PDGF-BB or other signalling pathways under inflammation (Fig. S3). To 
address whether Id2 transduces PDGF-BB signals to VEGF-A secretion, we examined the function of Id2 in 
MCs. We established primary cell lines from Id2 knockout mice and wild type mice, respectively18 (Fig. 6l,m). In 
wild-type MCs, PDGF-BB stimulation induced VEGF-A secretion and phosphorylation of STAT3. In contrast, 
these effects were almost eliminated in Id2-null MCs (Fig. 6n). Moreover, we investigated the effects of PDGF-BB 
on cell proliferation of MCs via Id2. PDGF-BB time-dependently increased the cell number and DNA synthesis 
Figure 3. Generation and characterization of Smad1-CKO mice. (a) Tamoxifen-inducible LacZ expression 
of glomeruli in ROSA26R Cre reporter/R26CreERT2 mice. Mice were sacrificed after 1 week of tamoxifen 
treatment. (b) qPCR analysis of Smad1 in the glomeruli isolated from LCM. The values are expressed as the 
mean ± SD. (*P < 0.05 compared to WT mice; n = 3). (c) Western blot analysis of Smad1 in the glomeruli 
isolated using the magnetic beads perfusion method. Body weight (d) and blood pressure (e) in control mice 
and CKO mice at the indicated times. (n = 4–6) (f) Histological analysis of the glomeruli of mice at 10 weeks. 
Representative sections from each mice kidney are shown (n = 4–6).
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Figure 4. Smad1-CKO mice showed less renal injury and albuminuria than did wild-type mice with NTN. 
Smad1-CKO and WT mice treated with NTS-injection and control mice were dissected 21 weeks after treatment 
(n = 6 in each group). Light microscopic and immunohistochemical analyses were performed. Representative 
microscopic appearance of the glomerulus is shown. (a–d) PAM. (e–h) Col 4. (i–l) pSmad1. (m–p) Col1. 
(q–t) αSMA. Original magnification for all panels was ×400. (u) PAM staining-positive area of the glomeruli. 
We collected at least 20 glomeruli in each sample. (v) The expression levels of Col4 (Col4a1 and Col4a2) in 
the glomeruli 21 d after the initial NTS injection were analysed by qPCR and normalized to the expression of 
Rn18s. The values are expressed as the mean ± SD. *P < 0.05. (w) The number of cells positive for pSmad1. Fifty 
glomeruli were analysed for each sample. The values are expressed as the mean ± SD. *P < 0.05. The expression 
levels of αSMA (x) and Col1a2 (y) in the glomeruli 21 d after the initial NTS injection were analysed by qPCR and 
normalized to the expression of Rn18s. The values are expressed as the mean ± SD. *P < 0.05. (z) Time course of 
changes in urinary albumin excretion in the two groups – WT mice (○) and Smad1-CKO mice (●) – after injection 
of NTS, and serum Cre and BUN levels at day 21.. Statistical analysis for comparison between CKO and control 
mice was performed using unpaired two-tailed Student’s t-test. NS, not significant, *P < 0.05 (n = 4–5 mice/group).
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in wild-type MCs. In contrast, these proliferative changes were suppressed in Id2-null MCs (Fig. S2). Collectively, 
these results suggest that Id2 transduces the PDGF signal to VEGF-A and STAT3 independently of Smad1 expres-
sion in MCs.
Discussion
Glomerulosclerosis is a common final lesion in various glomerular diseases and is characterized by mesangial 
ECM expansion. Overproduction of ECM is a critical feature in the progression of glomerular diseases toward 
end-stage renal disease, and halting the increase in ECM production may have some preventive effects for 
Figure 5. Proliferative changes were not observed in Smad1-CKO mice with NTN. Smad1-CKO and WT 
mice treated with NTS-injection and control mice were dissected 21 weeks after treatment (n = 6 in each 
group). Immunohistochemical analyses were performed. Representative microscopic appearance of the 
glomerulus is shown. (a–d) PDGF-B. (e–h) PDGFβR. (i–l) pSTAT3. (m–p) PCNA. Original magnification 
for all panels was ×400. We collected at least 20 glomeruli in each sample. (q) The expression levels of PDGF 
signals in the glomeruli 21 d after the initial NTS injection were analysed by qPCR and normalized to the 
expression of Rn18s. The values are expressed as the mean ± SD. *P < 0.05 The number of cells positive for 
pSTAT3 (r) and PCNA (s) was analyzed using fifty glomeruli from each sample. The values are expressed as the 
mean ± SD. *P < 0.05.
www.nature.com/scientificreports/
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progression to renal insufficiency. As increasing evidence supports the role of glomerular cell proliferation in the 
development of glomerulosclerosis, control of proliferative changes in glomerular cells is also important. In many 
Figure 6. Evaluation for changes of PDGF signalling and cell proliferation under the influence of Smad1 
silencing. (a) Effects of RNAi-mediated silencing of Smad1 on cell proliferation of MCs stimulated with 
PDGF-BB. Phosphorylation of Smad1 protein and STAT3 protein in MCs were monitored by western blotting. 
β-actin was used as a loading control. One of three independent experiments is shown. Immunohistochemical 
and quantitative analysis using qPCR of VEGF-A (b–e,f) and Id2 (g–j,k) in glomeruli in NTN. Data from  
qPCR were normalized to the expression of Rn18s. The values are expressed as the mean ± SD. *P < 0.05.  
(l) Confirmation of wild-type and null genotypes with PCR analysis of the Id2 deletion on genomic DNA 
obtained from the MCs. M: marker. (m) Western blot analysis of Id2 protein expression in MCs. β-actin was 
used as a loading control. (n) Phosphorylation of STAT3 protein and secretion of VEGF-A protein in wild-
type and Id2-null MCs were monitored by western blotting. β-actin was used as a loading control. One of three 
independent experiments is shown.
www.nature.com/scientificreports/
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glomerular diseases, in particular GN, proliferation of intrinsic glomerular cells precedes glomerulosclerosis. In 
this study, we provided strong in vivo evidence that mesangial matrix expansion and the overexpression of ECM 
proteins such as α1 and α2 chains of Col4 were specifically inhibited by Smad1 gene ablation, but that cell prolif-
eration and STAT3 activation were not affected in an experimental model of progressive proliferative nephritis. 
Therefore, the signalling pathways responsible for mesangial matrix expansion and cell proliferation in glomeruli 
in accelerated nephrotoxic nephritis are not the same. This difference may hold the key to solving issues concern-
ing plasticity in various kinds of GN.
During the progression of glomerular injuries, MCs can undergo phenotypic modulation, in which they mark-
edly up-regulate the expression of Col419. Col4 is a major component of the ECM, and we have demonstrated 
that Smad1 transcriptionally induces Col4 expression in vitro4. Thus we hypothesized that Smad1 may play a role 
in the progression towards glomerulosclerosis in GN. So far, no study has addressed the effect of gene ablation 
of Smad1 in glomerular disease because conventional Smad1 knockout mice are embryonic lethal. In addition, 
since there are no MC-specific Cre recombinases, we used Rosa26-CreERT2 mice to generate Smad1-CKO mice. 
Furthermore, Cre recombinase is known to have possible toxic effects on hematopoietic cells. Thus, to avoid the 
influence of Cre toxicity, we first created an appropriate control group of mice that contained only activated Cre 
recombinase. We then injected the mice with NTS one month after the administration of tamoxifen (TM) when 
the complete recovery of haematological toxicity was demonstrated. Finally, we minimized the dose of TM20 
administered. Some phenotypic abnormalities may be expected to appear in Smad1-CKO mice, as previous stud-
ies have shown that Smad1 is closely related to some cancers, bone formation and fibroblast-related skin diseases 
in adult mice21–23. However, these mice did not show abnormalities in any organs, including the glomeruli in the 
kidneys.
Although the Thy1 nephritis rat model is a good experimental model of rapidly progressive GN, this model 
often follows a self-limited course with spontaneous restitution of the glomerular architecture. Hence we selected 
the NTN model, which exhibits severe and progressive mesangial sclerosis, to investigate the key features that 
lead to irreversible and sustained changes in glomeruli. We sacrificed the mice 21 days after injection because 
glomerular injury was more prominent at day 21 than at day 7 or 1411. According to our previous study that found 
that Smad1 regulates the expression of Col4, Col1, and αSMA, resulting in ECM expansion in vitro4,24, we demon-
strated a similar role of Smad1 in the NTN model. However, in contrast to the results observed in Thy1 nephritis, 
deletion of Smad1 had no effects on the proliferative changes in glomeruli in the NTN model, suggesting that 
activation of another signalling pathway may transduce PDGF-BB signals to the phosphorylation of STAT3 inde-
pendently of Smad1 activation.
PDGF-BB is generally known as an essential mediator of mesangioproliferative nephritis. Overexpression of 
PDGF-BB increases the number of MCs and causes mesangial matrix expansion, leading to sclerosis of the glo-
meruli. STAT3 is recognized as a downstream target of PDGF-BB, and activated STAT3 contributes to cell-cycle 
proliferation, mitogenesis and chemotaxis25,26. However, it has remained undetermined what molecule directly 
transduces PDGF-BB signals to sclerotic and proliferative changes in progressive GN. In this study, we demon-
strated clearly that Smad1 plays a critical role in the production of ECM proteins that subsequently lead to glo-
merulosclerosis. However, persistent activation of PDGF signalling may facilitate proliferative changes through 
the Id2-VEGF signalling pathway independently of Smad1 in MCs. Although APB5 is a highly workable mono-
clonal anti-PDGFβR antibody, PDGF-BB also binds other type-A receptors such as PDGFαR. Thus, there is other 
possibilities that Id2-VEGF signalling pathway is activated from other upstream molecules that is activated by 
PDGF or inflammatory stimulation (Fig. S3). Particularly in humans, glomerulonephritis can vary in severity. It 
can often be chronic – that is, it can last for a long time, and it can lead to irreversible damage in the glomeruli, 
interfering with kidney function and resulting in kidney failure. Therefore, it is critically important to elucidate 
the detailed mechanisms determining the irreversible glomerular changes related to poor prognoses. Further 
investigation regarding the role of the Id2-VEGF signalling pathway in vivo is required.
Effective resolution of inflammation requires cessation of proliferative changes in the process of GN. Some 
recent reports have heightened awareness of the fact that resolution is an active process that requires activation 
of endogenous programs that enable the host tissue to maintain homeostasis26–28. We here confirmed that Smad1 
plays a pivotal role in ECM accumulation in glomerulonephritis using Smad1-CKO mice in vivo. Moreover, we 
also revealed that the Id2-VEGF-A-pSTAT3 pathway plays an important role in sustained cell proliferation of 
MCs independently of Smad1 expression. To provide a robust proof, NTN nephritis in conditional Id2-deleted 
mice should be investigated, because Id2–/– mice were born looked feeble, and their body size was very small 
compared with that of Id2+/+ or Id2+/– littermates18, and cannot bear the burden of administration of NTN. 
We think that this point is a limitation of this study. In addition, in the light of clinical assessment, the next 
task should involve longer-term observation of chronic proliferative glomerulonephritis in humans. Collectively, 
these results suggest that an imbalance between ECM accumulation and proliferative changes in the glomeruli 
may result in the irreversible progression of glomerulonephritis, leading to end stage kidney failure. Therapeutic 
approaches for irreversibly progressive glomerular diseases are currently limited to supportive therapy to slow the 
loss of function of the kidney. Our findings offer insights into the nature of the resolution of proliferative diseases 
and may provide potential therapeutic targets for inhibiting the progression of various renal diseases that lead to 
kidney failure. Combining with our overall findings summarized in Fig. S3, we can speculate that activation of 
Id2-VEGF signals under inflammation leading to sustained cell proliferation is a critical event in the development 
of glomerulosclerosis.
Materials and Methods
Animals. C57BL/6J mice were obtained from Shimizu Laboratory Animal Center (Hamamatsu, Japan). 
Rosa26CreERT2 mice were purchased from ARTEMIS Pharmaceuticals (Cologne, Germany)29. Smad1flox/− mice30 
were gifts from Dr. Anita B. Roberts and R26R Cre reporter mice (R26R mice)31 were gifts from Dr. P. Soriano. 
www.nature.com/scientificreports/
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Mice were genotyped by PCR and were backcrossed for more than ten generations into C57BL/6 mice. All mice 
were housed under specific pathogen-free conditions. Mice were euthanized by carbon dioxide inhalation. All 
animal experiments were performed in accordance with institutional guidelines, and full details of the ani-
mal experimental protocols were approved and ethical permission was granted by the Review Board of Kyoto 
University.
Induction of Accelerated NTN. From a previous paper32, decline of renal function was reported to depend 
on the amount of administrated NTS. Specifically, C57BL/6J mice with 0.2 ml of NTS daily injection were all dead 
within 10 days due to renal failure. Hence, we decided the dose of NTS as 0.1 ml. NTS33 was kindly provided by 
Dr. David J. Salant. Male mice (8 weeks old) were sensitized by subcutaneous injection of 1 mg of normal sheep 
IgG in Freund’s complete adjuvant in divided doses. Five days later, mice were injected with 0.1 ml of NTS daily 
for 3 days. Twenty-one days after the initial NTS injection, the mice were sacrificed, and their kidneys were 
examined.
Treatment with Anti-PDGFβ-R Antibody in Accelerated NTN. A rat monoclonal anti-PDGFβR 
antibody (APB5) and its antagonistic effects on the PDGFβR signal transduction pathway in vivo and in vitro 
have been described previously12,13. Mice were injected intraperitoneally with 1 mg of APB5 or irrelevant 
isotype-matched control rat IgG once a day after the administration of nephrotoxic serum (NTS).
Generation of conditional Smad1 KO mice. To generate conditional inducible Smad1 knockout mice, 
we bred Smad1flox/− mice with Rosa26CreERT2 mice, which express a tamoxifen-inducible form of the Cre recom-
binase from the ubiquitous Rosa26 locus. Tamoxifen (Sigma-Aldrich, MO) was dissolved in a sunflower oil/
ethanol (9/1) mixture and injected intraperitoneally at a dose of 2 mg/20 g body weight for 5 consecutive days. 
Knockdown of Smad1 was confirmed using qPCR and Western blot.
Histological Studies. One-third of each kidney was fixed in methyl Carnoy’s solution and embedded in 
paraffin. Sections (1 μm) were stained with periodic acid-Schiff and periodic acid methenamine silver (PAM) 
for routine histological examination. Portions of the kidney slices were mounted in Tissue-Tek OCT compound 
(Sakura Finetechnical, Tokyo, Japan) and snap-frozen. The other slices were fixed in 4% paraformaldehyde (PFA) 
and embedded in paraffin. Four micrometer-thick cryostat sections and 1-μm-thick paraffin sections were pre-
pared. Paraffin embedded kidney sections were rehydrated, boiled for 15 min at 105 °C in citrate buffer (pH 6.0) 
and treated with 0.3% H2O2 in methanol for 30 min. Sections were blocked with the appropriate preimmune 
serum and then incubated with Avidin D and Biotin blocking solutions (Vector, CA). Sections were incubated 
first with the rabbit anti-PCNA, anti-PDGF-BB (Santa Cruz, CA), anti-VEGF-A (proteintech), and Id2 (Santa 
Cruz) polyclonal antibodies overnight at 4 °C, then with the appropriate biotinylated secondary antibodies and 
finally with the Vectastain Elite ABC kit (Vector). We used the ABC kit without boiling for the staining of the rab-
bit anti-α-SMA polyclonal antibody (Thermo Scientific, MA). Peroxidase conjugates were subsequently localized 
using diaminobenzidine. Instead of the ABC kit, the TSA system (Perkin-Elmer, Life Science, Ontario, Canada) 
was applied for the detection of the rabbit anti-pSmad1/5/8 (Millipore, CA) and anti-pSTAT3 antibodies (Cell 
Signaling Technology, MA). For detection of the goat anti-Col4 (PROGEN, Heidelberg, Germany) and rabbit 
anti-Col1 polyclonal antibodies (GeneTex, CA), the slides were treated with 0.1% protease VIII (Sigma-Aldrich) 
for 20 min at room temperature. Four-μm-thick cryostat kidney sections were fixed in cold acetone for 10 min 
and treated with 0.3% hydrogen peroxide in methanol for 30 min. After an appropriate blocking step, the sections 
were incubated with the rabbit anti-PDGF-B polyclonal antibody (Santa Cruz) overnight at 4 °C. The process for 
using the secondary antibodies, Vectastain Elite ABC kit and diaminobenzidine was the same as described above. 
When we used the rabbit anti-β-galactosidase (Millipore) and anti-Desmin polyclonal antibodies (Abcam, MA), 
we substituted cold acetone for 4% PFA at room temperature.
Morphometric analyses. Staining density of mesangial matrix area as the PAM-positive area was analysed 
using Image-Pro Plus (Roper Industries, FL). The mesangial matrix fraction was determined as a percentage of 
the mesangial PAM-positive area per total glomerular surface area. For each animal, 50 glomeruli were analysed.
LCM and qPCR analysis. Glomeruli were obtained from the mice by laser-manipulated microdissec-
tion methods using the Robot-Microbeam (P.A.L.M., Wolfratshausen, Germany) and an inverted microscope 
(CarlZeiss, Oberkochem, Germany). For each experiment, 20–40 glomeruli were collected, and total RNA 
was extracted from the glomeruli using the Pico Pure RNA Isolation Kit (Molecular Devices, CA) according 
to the manufacturer’s protocol. Reverse transcription from mRNA to cDNA was performed using SuperScript 
reverse transcription kits (Invitrogen, CA). Amplification was conducted in an ABI Prism 7900 Sequence 
Detection System (Roche, Basel, Switzerland) using TaqMan gene expression assays (Applied Biosystems, CA). 
Normalization was performed using Rn18s as internal standards. TaqMan assay ID number used for PCR ampli-
fication for each gene transcript were listed in table 1. For αSMA, custom TaqMan Gene Expression Assays were 
used that had the following primers and probes: forward primer 5′-ACCGACTACCTCATGAAGATCCT-3′, 
reverse primer 5′-GCACAGCTTCTCCTTGATGTCA-3′. The cycling parameters were 10 minutes at 95 °C, fol-
lowed by 50 cycles of 15 sec at 95 °C and 60 sec at 60 °C. The other TaqMan gene expression assays used were as 
follows: Mm00484723_m1 (Smad1), Mm00483888_m1 (Col1 alpha 2 chain), Mm01210125_m1 (Col4 alpha 1 
chain), Mm00802386_m1 (Col4 alpha 2 chain), Mm01298578_m1 (PDGF-B), Mm00435546_m1 (PDGFR-β), 
Mm00711781_m1 (Id2), and Mm00437306_m1 (VEGF-A).
Western Blotting. Glomeruli were isolated using the magnetic beads perfusion method (Dynabead, 
Invitrogen/Dynal, Oslo, Norway)34. Isolated glomeruli were suspended in RIPA buffer (50 mM Tris, pH 7.5; 
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150 mM NaCl; 1% Nonidet P-40; 0.25% SDS; 1 mM Na3VO4; 2 mM EDTA; 1 mM phenylmethylsulfonyl fluoride; 
and 10 mg/ml of aprotinin) for 1 h at 4 °C. After centrifugation, the supernatants were used as total glomerular 
lysates. Each sample (10 μg) was subjected to SDS-PAGE. After electrophoresis, the proteins were transferred to 
nitrocellulose filters (Schleicher & Schuell). The blots were subsequently incubated with the rabbit anti-pSTAT3, 
Smad1 (Cell Signaling Technology), Id2 (Santa Cruz), VEGF-A (proteintech) and mouse β-actin (Cell Signaling 
Technology) polyclonal antibodies, followed by incubation with horseradish peroxidase-conjugated secondary 
antibody (Amersham Biosciences/GE Healthcare, Little Chalfont, UK). The immunoreactive bands were visu-
alized using an enhanced chemiluminescent system (Amersham Biosciences). Quantitative analysis of the band 
density was performed using Image Gauge (Fuji Photo Film Co. Ltd., Kanagawa, Japan).
Serum and Urine Examination. Urinary albumin excretion was measured at intervals from 0 to 21 days in 
24-hour urine collection samples from mice housed in individual metabolic cages. During the urine collection, 
the mice were allowed free access to food and water. Albumin concentration in the urine was measured using 
the Albuwell kit (Exocell Inc., PA). Levels of serum creatinine and blood urea nitrogen were measured at day 21.
Measurement of blood pressure. Systolic blood pressure (SBP) was measured every 2 weeks after surgery 
using a non-invasive computerized tail cuff system (Blood Pressure Analysis System BP- 98AW monitor, Softron 
Co., Ltd., Tokyo, Japan).
Establishment of cell lines. Glomerular MCs were established from glomeruli isolated from Id2 
knockout18 mice (kindly provided by Dr. Y. Yokota) and their control littermates (strain background 129/
sv) and were identified according to the method described previously35. MCs were maintained in B medium 
(a 3:1 mixture of minimal essential medium/F12 modified with trace elements) supplemented with 1 mM 
glutamine, penicillin at 100 units/ml, streptomycin at 100 mg/ml, and 20% fetal calf serum. The cultured cells 
fulfilled the generally accepted criteria for glomerular MCs34. Confirmation of wild-type and null genotypes 
were performed by using PCR with primers: Id2-S 5′-TCTGAGCTTATGTCGAATGATAAGC-3′, Id2-AS 
5′-CGTGTTCTCCTGGTGAAATGGCTG-3′, and neo-1 5′-TCGTGCTTTACGGTATCGCCGCTC-3′.
Small-interfering RNA. MCs (0.5 × 105) were seeded into 12-well plates (Nunc) and were grown until they 
were 60% to 80% confluent. The small-interfering RNAs (siRNAs) for Smad1 (Dharmacon) or control scrambled 
siRNA (Dharmacon) were combined with INTERFERin transfection reagent (Polyplus), and the cells were trans-
fected according to the recommended protocol with siRNA (20 nM final concentration). After 48 h of transfec-
tion, cells were starved in DMEM containing 0.5% BSA before treatment. After 24 h of addition of APB5 (100 ng/
dl), the cells were stimulated with or without PDGF-BB (Calbiochem).
BrdU proliferation assay. We performed BrdU proliferation assay to investigate whether Id2 affects the 
cell proliferation of MCs. MCs were were seeded into a 96-well microplate at a density of 104 cells/well in B 
medium/10% FCS. The proliferation of MCs was determined at 24, 48, and 72 hours using a colorimetric immu-
noassay based on the measurement of BrdU incorporation during DNA synthesis, according to the instruction of 
CycLex BrdU Cellular ELISA Kit (MBL International).
Statistical analysis. The data are expressed as the mean ± SD. Statistical analysis for comparison between 
CKO mice and control mice was performed using unpaired two-tailed Student’s t-test. Linear regression analysis 
was performed to evaluate the association between Smad1 and Col4 mRNA expression levels. A P-value <0.05 
was considered to be statistically significant.
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